TY - JOUR
T1 - Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures
AU - Zelber-Sagi, Shira
AU - Nitzan-Kaluski, Dorit
AU - Halpern, Zamir
AU - Oren, Ran
PY - 2006/9
Y1 - 2006/9
N2 - Background/Aims: Only a few studies have assessed the epidemiology of non-alcoholic fatty liver disease (NAFLD). The aim was to evaluate the prevalence of primary NAFLD in a population-based study in Israel and to determine independent risk factors. Methods: A cross-sectional study of a subsample of the Israeli national health survey (n = 352). Individuals with a known etiology for secondary NAFLD were excluded. Each participant underwent an abdominal ultrasound, biochemical tests and an anthropometric evaluation. Results: Three hundred and twenty-six subjects (53.4% male, mean age 50.5 ± 10.3 standard deviaton [SD]) met the inclusion criteria. The prevalence of primary NAFLD was 30% (25-35% 95% confidence intervals [CI]). NAFLD was more prevalent in men than women (38% vs. 21% P = 0.001). Compared with ultrasonography, the sensitivity of serum alanine transaminase (ALT) for the diagnosis of primary NAFLD was 8.2%. Risk factors independently associated with NAFLD included male gender (odds ratios (OR) = 2.8, 95% CI 1.5-5.3), abdominal obesity (OR = 2.9, 95% CI 1.3-6.4), homeostasis model assessment (OR = 5.8, 95% CI 2.0-17.2), hyperinsulinemia (OR = 2.3, 95% CI 1.2-4.3, P = 0.01) and hypertriglyceridemia (OR = 2.4, 95% CI 1.3-4.5). Conclusions: NAFLD is prevalent in the general Israeli population and closely related to the metabolic syndrome. The use of ALT as a marker for NAFLD seriously underestimates its prevalence.
AB - Background/Aims: Only a few studies have assessed the epidemiology of non-alcoholic fatty liver disease (NAFLD). The aim was to evaluate the prevalence of primary NAFLD in a population-based study in Israel and to determine independent risk factors. Methods: A cross-sectional study of a subsample of the Israeli national health survey (n = 352). Individuals with a known etiology for secondary NAFLD were excluded. Each participant underwent an abdominal ultrasound, biochemical tests and an anthropometric evaluation. Results: Three hundred and twenty-six subjects (53.4% male, mean age 50.5 ± 10.3 standard deviaton [SD]) met the inclusion criteria. The prevalence of primary NAFLD was 30% (25-35% 95% confidence intervals [CI]). NAFLD was more prevalent in men than women (38% vs. 21% P = 0.001). Compared with ultrasonography, the sensitivity of serum alanine transaminase (ALT) for the diagnosis of primary NAFLD was 8.2%. Risk factors independently associated with NAFLD included male gender (odds ratios (OR) = 2.8, 95% CI 1.5-5.3), abdominal obesity (OR = 2.9, 95% CI 1.3-6.4), homeostasis model assessment (OR = 5.8, 95% CI 2.0-17.2), hyperinsulinemia (OR = 2.3, 95% CI 1.2-4.3, P = 0.01) and hypertriglyceridemia (OR = 2.4, 95% CI 1.3-4.5). Conclusions: NAFLD is prevalent in the general Israeli population and closely related to the metabolic syndrome. The use of ALT as a marker for NAFLD seriously underestimates its prevalence.
KW - ALT
KW - Metabolic syndrome
KW - NAFLD
KW - Prevalence
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=33746700131&partnerID=8YFLogxK
U2 - 10.1111/j.1478-3231.2006.01311.x
DO - 10.1111/j.1478-3231.2006.01311.x
M3 - Article
C2 - 16911469
AN - SCOPUS:33746700131
SN - 1478-3223
VL - 26
SP - 856
EP - 863
JO - Liver International
JF - Liver International
IS - 7
ER -